Management of Mandibular ORN: PENTO as Medical Treatment

Inclusion Criteria: * Over 18 years and under 90 years old. * Patients who have received radiotherapy after being diagnosed with head and neck cancer and currently are diagnosticated of mandibular osteoradionecrosis (any clinical stage) * Follow-up for at least a year after the radiation treatment is completed. * Absence of tumor at the time of recruitment. * Patients with the capacity to give informed consent Exclusion Criteria: * Allergy or hypersensitivity to Pentoxifylline or others xanthines, or to Tocopherol (vitamin E). * Patients taking oral anticoagulants (acenocoumarol, warfarin). * Known hemorrhagic/coagulation disorder. * Vitamin K deficiency due to any cause. * Use of estrogens oral contraceptives. * Serious bleeding or extensive retinal hemorrhage. * Ischaemic heart diseases, including recent Myocardial Infarction. * Serious cardiac arrhythmia. * Severe LIVER DISEASE. * Severe renal failure (creatinine clearance \<30 mL/min). * Hypotension. * Female patients who are pregnant or lactating * Any other situation or condition that, in the opinion of the INVESTIGATOR, may interfere with optimal PARTICIPATION in the study.